Prozac (Fluoxetine) Onsite Taper

Fluoxetine is handled individually rather than assumed to follow the standard onsite taper. It and its active metabolite norfluoxetine clear far more slowly than any other SSRI — ≈ 1–4 days (parent), 4–16 days (norfluoxetine metabolite) — so your timing is confirmed with our medical team before you travel. Tell our team you take Prozac during screening so your plan is built around the metabolite-clearance window rather than a fixed schedule. A small number of other medications — MAOIs, lithium, tricyclic antidepressants, tramadol and certain QT-prolonging cardiac medications — do still need to be cleared before you arrive, so our medical team reviews your full medication list in advance.

Typically 14–21 days onsite (driven by metabolite clearance, not parent drug). That range is driven by fluoxetine's long half-life — ≈ 1–4 days (parent), 4–16 days (norfluoxetine metabolite) — and your baseline dose, usually 10–80 mg/day. Reductions are hyperbolic rather than linear, so the schedule follows how you actually respond instead of running to a fixed calendar.

The fluoxetine discontinuation profile covers: Withdrawal is typically delayed and milder than short-half-life SSRIs; Late-onset emotional blunting reversal — irritability, lability, vivid dreams; Anxiety rebound 2–4 weeks after final dose; GI distress, fatigue. The onsite protocol bridges the taper with sub-psychoactive iboga total alkaloid (50–150 mg BID for full bridge window) to cover the receptor-occupancy gap as your dose comes down, with symptom-driven support and continuous monitoring throughout.

Long norfluoxetine tail makes home-taper feel deceptively easy until the metabolite clears, then symptoms emerge weeks later. Patients often relapse at week 3–4 because they no longer associate symptoms with the discontinuation. Hyperbolic micro-dosing below 10 mg requires compounded preparation.

Yes. Direct discontinuation is feasible for many patients given the long norfluoxetine tail. Iboga TA bridge 50–150 mg BID for 14–21 days to cover the metabolite-clearance window. Continuous cardiac telemetry across the entire bridge. Magnesium pre-loading; electrolyte normalization before any flood-dose ibogaine HCl.

A flood dose of ibogaine HCl is only administered once fluoxetine has been reduced to a protocol-defined safe threshold and your cardiac screening is still within limits — eligibility is confirmed at that point rather than promised in advance. Ibogaine is an investigational compound, is not approved by the FDA, and results vary between patients. If your medication picture or your screening makes treatment unsafe, we will tell you honestly.